Rigel Pharmaceuticals Inc RIGL
Find similar stocks with Morningstar Investor.
Morningstar analysts do not currently cover RIGL, but with our powerful screener, you can find
stocks in the same sector,industry, or style and filter on our unbiased ratings and valuation metrics.
News
-
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
-
Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML
-
Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and Taiwan
-
Rigel to Participate in Upcoming September Investor Conferences
-
Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update
-
Rigel Announces Conference Call and Webcast to Report Second Quarter 2024 Financial Results and Business Update
-
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $16.05
- Day Range
- $15.82–16.46
- 52-Week Range
- $7.12–17.30
- Bid/Ask
- $16.04 / $17.10
- Market Cap
- $282.22 Mil
- Volume/Avg
- 62,060 / 151,105
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.15
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 147
- Website
- https://www.rigel.com
Comparables
Valuation
|
Metric
|
RIGL
|
ARQT
|
EPIX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 6.36 | 2.08 |
Price/Sales | 2.15 | 7.50 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
RIGL
|
ARQT
|
EPIX
|
|---|---|---|---|
Quick Ratio | 1.33 | 7.90 | 36.61 |
Current Ratio | 1.62 | 8.46 | 36.95 |
Interest Coverage | −1.17 | −5.45 | −29,635.69 |
Quick Ratio
RIGL
ARQT
EPIX
Profitability
|
Metric
|
RIGL
|
ARQT
|
EPIX
|
|---|---|---|---|
Return on Assets (Normalized) | −2.34% | −44.22% | −15.52% |
Return on Equity (Normalized) | — | −132.42% | −15.94% |
Return on Invested Capital (Normalized) | 7.82% | −42.92% | −19.88% |
Return on Assets
RIGL
ARQT
EPIX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Sdzvtppy | Kgtj | $516.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Nbtmhbc | Pxhjkn | $117.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Fxxjdbdzh | Qwwnqw | $111.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Vdzdksjpw | Xszbqd | $34.6 Bil | |||
| argenx SE ADR
ARGX
| Kvbltjbl | Gtky | $33.0 Bil | |||
| BioNTech SE ADR
BNTX
| Ghlhznpy | Jvdhs | $28.5 Bil | |||
| Moderna Inc
MRNA
| Rblwqwy | Xyrfw | $23.5 Bil | |||
| United Therapeutics Corp
UTHR
| Mpcbxqnm | Jpfs | $15.6 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Bpjxnvfhw | Whvvxs | $13.0 Bil | |||
| Incyte Corp
INCY
| Nyxvnrrq | Tqwqtc | $12.9 Bil |
United States